201 related articles for article (PubMed ID: 25752567)
1. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
Blondeau JM; Shebelski SD; Hesje CK
Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
[TBL] [Abstract][Full Text] [Related]
4. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
[TBL] [Abstract][Full Text] [Related]
5. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
[TBL] [Abstract][Full Text] [Related]
6. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Davies TA; Kelly LM; Pankuch GA; Credito KL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939
[TBL] [Abstract][Full Text] [Related]
8. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Blondeau JM; Blondeau LD; Hesje C; Borsos S
J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
10. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae.
Morozumi M; Okada T; Tajima T; Ubukata K; Iwata S
Int J Antimicrob Agents; 2017 Aug; 50(2):255-257. PubMed ID: 28579455
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Visalli MA; Jacobs MR; Appelbaum PC
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
[TBL] [Abstract][Full Text] [Related]
12. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
13. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
[TBL] [Abstract][Full Text] [Related]
14. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
[TBL] [Abstract][Full Text] [Related]
15. Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates.
Oncü S; Punar M; Eraksoy H
Chemotherapy; 2004 Jun; 50(2):98-100. PubMed ID: 15211085
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro.
Anderson R; Steel HC; Cockeran R; von Gottberg A; de Gouveia L; Klugman KP; Mitchell TJ; Feldman C
J Antimicrob Chemother; 2007 Nov; 60(5):1155-8. PubMed ID: 17848373
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.
Waites KB; Crabb DM; Duffy LB
Int J Antimicrob Agents; 2003 Jun; 21(6):574-7. PubMed ID: 12791472
[TBL] [Abstract][Full Text] [Related]
20. CEM-101 activity against Gram-positive organisms.
Woosley LN; Castanheira M; Jones RN
Antimicrob Agents Chemother; 2010 May; 54(5):2182-7. PubMed ID: 20176910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
